1)Kalmann R, Mourits MP:Prevalence and management of elevated intraocular pressure in patients with Graves'orbitopathy. Br J Ophthalmol 82:754-757, 1998
2)da Silva FL, de Lourdes Veronese Rodrigues M, Akaishi PM et al:Graves'orbitopathy:frequency of ocular hypertension and glaucoma. Eye 23:957-959, 2009
3)Haefliger IO, von Arx G, Pimentel AR:Pathophysiology of intraocular prsssure increase and glaucoma prevalence in thyroid eye disease. A mini-review. Klin Monbl Augenheilkd 227:292-293, 2010
4)Nassr MA, Morris CL, Netland PA et al:Intraocular pressure change in orbital disease. Survey Opththalmol 54:519-544, 2009
5)Saunders RA, Helveston EM, Ellis FD:Differential intraocular pressure in strabismus diagnosis. Ophthalmology 88:59-70, 1981
6)吉川啓司:甲状腺眼症に伴う高眼圧.眼科診療プラクティス 98(緑内障のトラブルシューティング):107,2006
7)井上洋一:眼球突出に伴う緑内障.眼科診療プラクティス 10(緑内障診療の進め方):196-197,1990
8)Dev S, Damji KF, DeBacker CM et al:Decrease in intraocular pressure after orbital decompression for thyroid orbitopathy. Can J Ophthalmol 33:314-319, 1998
9)Norris JH, Ross JJ, Kazim M et al:The effect of orbital decompression surgery on refraction and intraocular pressure in patients with thyroid orbitopathy. Eye 26:535-543, 2012
10)Peplinski LS, Albiani Smith K:Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81:574-577, 2004
11)Park J, Cho HK, Moon JI:Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 55:22-27, 2011
12)Serrero G, Lepak NM:Prostaglandin F2alpha receptor(FP receptor)agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 233:200-202, 1997
13)Liu L, Clipstone NA:Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway. J Cell Biochem 100:161-173, 2007
14)Dayan CM, Dayan MR:Dysthyroid optic neuropathy:a clinical diagnosis or a definable entity? Br J Ophthalmol 91:409-410, 2007